BioSpace News Archive

The Geistlich Medical business unit of Geistlich Pharma AG, a family owned, Swiss-based global leader in regenerative solutions, is proud to announce the results from their clinical study of the Geistlich Derma-Gide® Advanced Wound Matrix.

Massive Bio, Inc announced the hiring of Steve McNamara as chief operating officer.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today provided a corporate update and highlighted key 2022 milestones in conjunction with its presentation at the 40th Annual J.P. Morgan Virtual Healthcare Conference.

TC BioPharm has appointed Chris Camarra to the newly created role of Executive Vice President, Communications.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), today announced it has observed significant decrease in viral load with prophylactic treatment of REVTx-99 in three independent in vitro single cell-based assay models of SARS-CoV-2 infection.

Vivera Pharmaceuticals announced , the appointment of Donald D’Ambrosio as the Company’s Chief Financial Officer.

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation and patient monitoring, today reported it has started enrollments in a clinical trial aimed at further characterizing the performance of its fluid monitoring system, CM-1500.

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval of Cochlear™ Nucleus® Implants for the treatment of unilateral hearing loss (UHL)/single-sided deafness (SSD).

Shanghai ZhenGe Biotech Co., Ltd. announced the completion of round C financing of US $100 million, led by Goldman Sachs Asset Management and Sofina.

Medical device and technology company Lazurite Holdings LLC today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its ArthroFree™ wireless camera system for minimally invasive surgery, and that the submission has been accepted for review.